Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 11
HOS-108840 · Präparat HOS-093083
Abacavir, Zidovudine Abacavir, Zidovudine: The clinical significance of
Concentrations may be reduced reduced abacavir and zidovudine
due to increased glucuronidation concentrations is unknown.
by lopinavir/ritonavir.
Tenofovir disoproxil Tenofovir: No dose adjustment necessary.
fumarate (DF), 300 mg QD AUC: ↑ 32% Higher tenofovir concentrations
Cmax: ↔ could potentiate tenofovir
(equivalent to 245 mg Cmin: ↑ 51% associated adverse events,
tenofovir disoproxil) including renal disorders.
Lopinavir: ↔
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Efavirenz, 600 mg QD Lopinavir: See section 4.2 for Kaletra dosage
AUC: ↓ 20% recommendation or consider
Cmax: ↓ 13% alternative therapy.
Cmin: ↓ 42%
Nevirapine, 200 mg BID Lopinavir: See section 4.2 for Kaletra dosage
AUC: ↓ 27% recommendation or consider
Cmax: ↓ 19% alternative therapy.
Cmin: ↓ 51%
Etravirine Etravirine: No dose adjustment necessary
AUC: ↓ 35%
(Lopinavir/ritonavir tablet Cmin: ↓ 45%
400/100 mg BID) Cmax: ↓ 30%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) etravirine (HOS-088088) tenofovir disoproxil (HOS-108843) fumarate (HOS-108845) zidovudine (HOS-085837) efavirenz (HOS-087947) nevirapine (HOS-088064) abacavir (HOS-088077)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 7e8d3e75ebcfb46fcb48f151d995ceb0e62959fafd1f9cc35b54c2dafa32e31e · Zeichen 2252–4083 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 47–48
HOS-109002 · Präparat HOS-093083
47
Tenofovir disoproxil Tenofovir: No dose adjustment necessary.
fumarate (DF), 300 mg AUC: ↑ 32% Higher tenofovir concentrations could
QD Cmax: ↔ potentiate tenofovir associated
Cmin: ↑ 51% adverse events, including renal
(equivalent to 245 mg disorders.
tenofovir disoproxil) Lopinavir: ↔
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Efavirenz, 600 mg QD Lopinavir: See section 4.2 for Kaletra dosage
AUC: ↓ 20% recommendation or consider
Cmax: ↓ 13% alternative therapy. Kaletra must not
Cmin: ↓ 42% be administered once daily in
combination with efavirenz.
Nevirapine, 200 mg Lopinavir: See section 4.2 for Kaletra dosage
BID AUC: ↓ 27% recommendation or consider
Cmax: ↓ 19% alternative therapy. Kaletra must not
Cmin: ↓ 51% be administered once daily in
combination with nevirapine.
Etravirine Etravirine: No dose adjustment necessary
AUC: ↓ 35%
(Lopinavir/ritonavir Cmin: ↓ 45%
tablet 400/100 mg BID) Cmax: ↓ 30%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) etravirine (HOS-088088) tenofovir disoproxil (HOS-108843) fumarate (HOS-108845) efavirenz (HOS-087947) nevirapine (HOS-088064)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 1aa214ec519e800876deb03695523d141ba93dc4735974a07c93601e327b046a · Zeichen 2765–4474 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 83
HOS-109075 · Präparat HOS-093083
Abacavir, Zidovudine Abacavir, Zidovudine: The clinical significance of reduced
Concentrations may be reduced abacavir and zidovudine
due to increased glucuronidation concentrations is unknown.
by lopinavir/ritonavir.
Tenofovir disoproxil Tenofovir: No dose adjustment necessary.
fumarate (DF), 300 mg AUC: ↑ 32% Higher tenofovir concentrations
QD Cmax: ↔ could potentiate tenofovir
Cmin: ↑ 51% associated adverse events, including
(equivalent to 245 mg renal disorders.
tenofovir disoproxil) Lopinavir: ↔
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Efavirenz, 600 mg QD Lopinavir: See section 4.2 for Kaletra dosage
AUC: ↓ 20% recommendation or consider
Cmax: ↓ 13% alternative therapy.
Cmin: ↓ 42% Kaletra must not be administered
once daily in combination with
efavirenz.
Nevirapine, 200 mg Lopinavir: See section 4.2 for Kaletra dosage
BID AUC: ↓ 27% recommendation or consider
Cmax: ↓ 19% alternative therapy.
Cmin: ↓ 51% Kaletra must not be administered
once daily in combination with
nevirapine.
Etravirine Etravirine: No dose adjustment necessary
AUC: ↓ 35%
(Lopinavir/ritonavir Cmin: ↓ 45%
tablet 400/100 mg BID) Cmax: ↓ 30%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) etravirine (HOS-088088) tenofovir disoproxil (HOS-108843) fumarate (HOS-108845) zidovudine (HOS-085837) efavirenz (HOS-087947) nevirapine (HOS-088064) abacavir (HOS-088077)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage c9296155c3ce5ef684722be8fb72dfceaf88100c0a3b2414e8bf3a028a9c0a3c · Zeichen 2392–4529 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 12
HOS-112073 · Präparat HOS-093615
No significant effect on atazanavir
concentrations was observed when
administered with enteric-coated
didanosine, but administration with food
decreased didanosine concentrations.
Tenofovir disoproxil fumarate Atazanavir AUC: ↓22% (↓35% ↓6%) * When co-administered with
300 mg once daily Atazanavir Cmax: ↓16% (↓30% ↔0%) * tenofovir disoproxil fumarate, it is
(atazanavir 300 mg once daily Atazanavir Cmin: ↓23% (↓43% ↑2%) * recommended that REYATAZ
with ritonavir 100 mg once daily) 300 mg be given with ritonavir
* In a combined analysis from several 100 mg and tenofovir disoproxil
300 mg tenofovir disoproxil clinical studies, atazanavir/ritonavir fumarate 300 mg (all as a single
fumarate is equivalent to 245 mg 300/100 mg co-administered with dose with food).
tenofovir disoproxil. tenofovir disoproxil fumarate 300 mg
(n = 39) was compared to
Studies conducted in HIV- atazanavir/ritonavir 300/100 mg (n = 33).
infected patients
The efficacy of REYATAZ/ritonavir in
combination with tenofovir disoproxil
fumarate in treatment-experienced patients
has been demonstrated in clinical
study 045 and in treatment naïve patients
in clinical study 138 (see sections 4.8
and 5.1). The mechanism of interaction
between atazanavir and tenofovir
disoproxil fumarate is unknown.
Tenofovir disoproxil fumarate Tenofovir disoproxil fumarate AUC: ↑37% Patients should be closely
300 mg once daily (↑30% ↑45%) monitored for tenofovir disoproxil
(atazanavir 300 mg once daily Tenofovir disoproxil fumarate Cmax: ↑34% fumarate-associated adverse
with ritonavir 100 mg once daily) (↑20% ↑51%) reactions, including renal disorders.
Tenofovir disoproxil fumarate Cmin: ↑29%
300 mg tenofovir disoproxil (↑21% ↑36%)
fumarate is equivalent to 245 mg
tenofovir disoproxil.
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Efavirenz 600 mg once daily Atazanavir (pm): all administered with Co-administration of efavirenz and
(atazanavir 400 mg once daily food REYATAZ is not recommended
with ritonavir 100 mg once daily) Atazanavir AUC: ↔0%(↓9% ↑10%)* (see section 4.4).
Atazanavir Cmax: ↑17%(↑8% ↑27%)*
Atazanavir Cmin: ↓42%(↓51% ↓31%)*
Efavirenz 600 mg once daily Atazanavir (pm): all administered with
(atazanavir 400 mg once daily food
with ritonavir 200 mg once daily) Atazanavir AUC: ↔6% (↓10% ↑26%)*/**
Atazanavir Cmax: ↔9% (↓5% ↑26%)*/**
Atazanavir Cmin: ↔12% (↓16% ↑49%)*/**
*When compared to REYATAZ
300 mg/ritonavir 100 mg once daily in the
evening without efavirenz. This decrease
in atazanavir Cmin might negatively impact
the efficacy of atazanavir. The mechanism
of efavirenz/atazanavir interaction is
CYP3A4 induction.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) tenofovir disoproxil (HOS-108843) didanosine (HOS-085836) fumarate (HOS-108845) efavirenz (HOS-087947) tenofovir disoproxil fumarate (HOS-110471) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 7bb7bde08aba3c87ff8884ed201528362530687526da177fc8f79451b0f7859f · Zeichen 13958–17928 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 15–16
HOS-112086 · Präparat HOS-093615
15
Medicinal products by Interaction Recommendations concerning co-
therapeutic area administration
ACID REDUCING AGENTS
H2-Receptor antagonists
Without Tenofovir
In HIV-infected patients with atazanavir/ritonavir at the recommended For patients not taking tenofovir,
dose 300/100 mg once daily if REYATAZ 300 mg/ritonavir
Famotidine 20 mg twice daily Atazanavir AUC: ↓18% (↓25% ↑1%) 100 mg and H2-receptor antagonists
Atazanavir Cmax: ↓20% (↓32% ↓7%) are co-administered, a dose
Atazanavir Cmin: ↔1% (↓16% ↑18%) equivalent to famotidine 20 mg
twice daily should not be exceeded.
Famotidine 40 mg twice daily Atazanavir AUC: ↓23% (↓32% ↓14%) If a higher dose of an H2-receptor
Atazanavir Cmax: ↓23% (↓33% ↓12%) antagonist is required (e.g.,
Atazanavir Cmin: ↓20% (↓31% ↓8%) famotidine 40 mg twice daily or
In healthy volunteers with atazanavir/ritonavir at an increased dose equivalent) an increase of the
of 400/100 mg once daily REYATAZ/ritonavir dose from
Famotidine 40 mg twice daily Atazanavir AUC: ↔3% (↓14% ↑22%) 300/100 mg to 400/100 mg can be
Atazanavir Cmax: ↔2% (↓13% ↑8%) considered.
Atazanavir Cmin: ↓14% (↓32% ↑8%)
With Tenofovir disoproxil fumarate 300 mg once daily (equivalent to 245 mg tenofovir disoproxil)
In HIV-infected patients with atazanavir/ritonavir at the recommended dose For patients who are taking
of 300/100 mg once daily tenofovir disoproxil fumarate, if
Famotidine 20 mg twice daily Atazanavir AUC: ↓21% (↓34% ↓4%)* REYATAZ/ritonavir with both
Atazanavir Cmax: ↓21% (↓36% ↓4%)* tenofovir disoproxil fumarate and
Atazanavir Cmin: ↓19% (↓37% ↑5%)* an H2-receptor antagonist are co-
administered, a dose increase of
Famotidine 40 mg twice daily Atazanavir AUC: ↓24% (↓36% ↓11%)* REYATAZ to 400 mg with 100 mg
Atazanavir Cmax: ↓23% (↓36% ↓8%)* of ritonavir is recommended. A
Atazanavir Cmin: ↓25% (↓47% ↑7%)* dose equivalent to famotidine
In HIV-infected patients with atazanavir/ritonavir at an increased dose 40 mg twice daily should not be
of 400/100 mg once daily exceeded.
Famotidine 20 mg twice daily Atazanavir AUC: ↑18% (↑6.5% ↑30%)*
Atazanavir Cmax: ↑18% (↑6.7% ↑31%)*
Atazanavir Cmin: ↑24% (↑10% ↑39%)*
Famotidine 40 mg twice daily Atazanavir AUC: ↔2.3% (↓13% ↑10%)*
Atazanavir Cmax: ↔5% (↓17% ↑8.4%)*
Atazanavir Cmin: ↔1.3% (↓10% ↑15)*
*When compared to atazanavir 300 mg
once daily with ritonavir 100 mg once
daily and tenofovir disoproxil fumarate
300 mg all as a single dose with food.
When compared to atazanavir 300 mg with
ritonavir 100 mg without tenofovir
disoproxil fumarate, atazanavir
concentrations are expected to be
additionally decreased by about 20%.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) famotidine (HOS-112087) tenofovir disoproxil (HOS-108843) fumarate (HOS-108845) tenofovir disoproxil fumarate (HOS-110471) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 695cfffb4426adfdcee429184e2620b1c5bb6af71aadbc31f5b2433e0455e449 · Zeichen 31489–35584 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 47
HOS-112172 · Präparat HOS-093615
No significant effect on didanosine and
stavudine concentrations was observed.
Didanosine (enteric coated Didanosine (with food)
capsules) 400 mg single dose Didanosine AUC: ↓34% (↓41% ↓27%)
(atazanavir 300 mg once daily Didanosine Cmax: ↓38% (↓48% ↓26%)
with ritonavir 100 mg once Didanosine Cmin: ↑25% (↓8% ↑69%)
daily)
No significant effect on atazanavir
concentrations was observed when
administered with enteric-coated
didanosine, but administration with food
decreased didanosine concentrations.
Tenofovir disoproxil Atazanavir AUC: ↓22% (↓35% ↓6%)* When co-administered with
fumarate 300 mg once daily Atazanavir Cmax: ↓16% (↓30% ↔0%)* tenofovir disoproxil fumarate,
(atazanavir 300 mg once daily Atazanavir Cmin: ↓23% (↓43% ↑2%)* it is recommended that
with ritonavir 100 mg once REYATAZ 300 mg be given
daily) *In a combined analysis from several with ritonavir 100 mg and
clinical studies, atazanavir/ritonavir tenofovir disoproxil fumarate
300 mg tenofovir disoproxil 300/100 mg co-administered with tenofovir 300 mg (all as a single dose
fumarate is equivalent to disoproxil fumarate 300 mg (n = 39) was with food).
245 mg tenofovir disoproxil. compared to atazanavir/ritonavir
300/100 mg (n = 33).
Studies conducted in HIV-
infected patients The efficacy of REYATAZ/ritonavir in
combination with tenofovir disoproxil
fumarate in treatment-experienced patients
has been demonstrated in clinical study 045
and in treatment naive patients in clinical
study 138 (see sections 4.8 and 5.1). The
mechanism of interaction between
atazanavir and tenofovir disoproxil
fumarate is unknown.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) stavudine (HOS-088080) tenofovir disoproxil (HOS-108843) didanosine (HOS-085836) fumarate (HOS-108845) tenofovir disoproxil fumarate (HOS-110471) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 85dd1351f7e7583a5f13a723d7100c44d38f3263361d690ef402b7958692fcf6 · Zeichen 13770–16089 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 47–48
HOS-112173 · Präparat HOS-093615
47
Medicinal products by Interaction Recommendations
therapeutic area concerning co-administration
Tenofovir disoproxil Tenofovir disoproxil fumarate AUC: ↑37% Patients should be closely
fumarate 300 mg once daily (↑30% ↑45%) monitored for tenofovir
(atazanavir 300 mg once daily Tenofovir disoproxil fumarate Cmax: ↑34% disoproxil fumarate-associated
with ritonavir 100 mg once (↑20% ↑51%) adverse reactions, including
daily) Tenofovir disoproxil fumarate Cmin: ↑29% renal disorders.
(↑21% ↑36%)
300 mg tenofovir disoproxil
fumarate is equivalent to
245 mg tenofovir disoproxil.
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Efavirenz 600 mg once daily Atazanavir (pm): all administered with Co-administration of efavirenz
(atazanavir 400 mg once daily food and REYATAZ is not
with ritonavir 100 mg once Atazanavir AUC: ↔0%(↓9% ↑10%)* recommended (see
daily) Atazanavir Cmax: ↑17%(↑8% ↑27%)* section 4.4).
Atazanavir Cmin: ↓42%(↓51% ↓31%)*
Efavirenz 600 mg once daily Atazanavir (pm): all administered with
(atazanavir 400 mg once daily food
with ritonavir 200 mg once Atazanavir AUC: ↔6% (↓10% ↑26%)*/**
daily) Atazanavir Cmax: ↔9% (↓5% ↑26%)*/**
Atazanavir Cmin: ↔12% (↓16% ↑49%)*/**
*When compared to REYATAZ
300 mg/ritonavir 100 mg once daily in the
evening without efavirenz. This decrease in
atazanavir Cmin might negatively impact the
efficacy of atazanavir. The mechanism of
efavirenz/atazanavir interaction is CYP3A4
induction.
**Based on historical comparison.
Nevirapine 200 mg twice Nevirapine AUC: ↑26% (↑17% ↑36%) Co-administration of
daily Nevirapine Cmax: ↑21% (↑11% ↑32%) nevirapine and REYATAZ is
(atazanavir 400 mg once daily Nevirapine Cmin: ↑35% (↑25% ↑47%) not recommended (see
with ritonavir 100 mg once section 4.4)
daily) Atazanavir AUC: ↓19% (↓35% ↑2%)*
Atazanavir Cmax: ↔2% (↓15% ↑24%)*
Study conducted in Atazanavir Cmin: ↓59% (↓73% ↓40%)*
HIV-infected patients.
*When compared to REYATAZ 300 mg
and ritonavir 100 mg without nevirapine.
This decrease in atazanavir Cmin might
negatively impact the efficacy of
atazanavir. The mechanism of
nevirapine/atazanavir interaction is
CYP3A4 induction.
Integrase Inhibitors
Raltegravir 400 mg twice Raltegravir AUC: ↑41% No dose adjustment required
daily Raltegravir Cmax: ↑24% for raltegravir.
(atazanavir/ritonavir) Raltegravir C12hr: ↑77%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) tenofovir disoproxil (HOS-108843) fumarate (HOS-108845) efavirenz (HOS-087947) tenofovir disoproxil fumarate (HOS-110471) raltegravir (HOS-086187) nevirapine (HOS-088064) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 2529640408b48ec38f79f5dff34d0e67815def643a3690b8554f5a5e2543b477 · Zeichen 16147–19757 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 50–51
HOS-112181 · Präparat HOS-093615
50
Medicinal products by Interaction Recommendations
therapeutic area concerning co-administration
Rifampicin Rifampicin is a strong CYP3A4 inducer The combination of rifampicin
and has been shown to cause a 72% and REYATAZ is
decrease in atazanavir AUC which can contraindicated (see
result in virological failure and resistance section 4.3).
development. During attempts to overcome
the decreased exposure by increasing the
dose of REYATAZ or other protease
inhibitors with ritonavir, a high frequency
of liver reactions was seen.
ANTIPSYCHOTICS
Quetiapine Due to CYP3A4 inhibition by REYATAZ, Co-administration of
concentrations of quetiapine are expected quetiapine with REYATAZ is
to increase. contraindicated as REYATAZ
may increase quetiapine-
related toxicity. Increased
plasma concentrations of
quetiapine may lead to coma
(see section 4.3).
Lurasidone REYATAZ is expected to increase plasma Co-administration of
levels of lurasidone due to CYP3A4 lurasidone with REYATAZ is
inhibition. contraindicated as this may
increase lurasidone-related
toxicity (see section 4.3).
ACID REDUCING AGENTS
H2-Receptor antagonists
Without Tenofovir
In HIV-infected patients with atazanavir/ritonavir at the recommended For patients not taking
dose 300/100 mg once daily tenofovir, if REYATAZ
Famotidine 20 mg twice daily Atazanavir AUC: ↓18% (↓25% ↑1%) 300 mg/ritonavir 100 mg and
Atazanavir Cmax: ↓20% (↓32% ↓7%) H2-receptor antagonists are co-
Atazanavir Cmin: ↔1% (↓16% ↑18%) administered, a dose equivalent
to famotidine 20 mg twice
Famotidine 40 mg twice daily Atazanavir AUC: ↓23% (↓32% ↓14%) daily should not be exceeded.
Atazanavir Cmax: ↓23% (↓33% ↓12%) If a higher dose of an H2-
Atazanavir Cmin: ↓20% (↓31% ↓8%) receptor antagonist is required
In healthy volunteers with atazanavir/ritonavir at an increased dose (e.g., famotidine 40 mg twice
of 400/100 mg once daily daily or equivalent) an increase
Famotidine 40 mg twice daily Atazanavir AUC: ↔3% (↓14% ↑22%) of the REYATAZ/ritonavir
Atazanavir Cmax: ↔2% (↓13% ↑8%) dose from 300/100 mg to
Atazanavir Cmin: ↓14% (↓32% ↑8%) 400/100 mg can be considered.
With Tenofovir disoproxil fumarate 300 mg once daily (equivalent to 245 mg tenofovir disoproxil)
In HIV-infected patients with atazanavir/ritonavir at the recommended dose For patients who are taking
of 300/100 mg once daily tenofovir disoproxil
Famotidine 20 mg twice daily Atazanavir AUC: ↓21% (↓34% ↓4%)* fumarate, if
Atazanavir Cmax: ↓21% (↓36% ↓4%)* REYATAZ/ritonavir with both
Atazanavir Cmin: ↓19% (↓37% ↑5%)* tenofovir disoproxil fumarate
and an H2-receptor antagonist
Famotidine 40 mg twice daily Atazanavir AUC: ↓24% (↓36% ↓11%)* are co-administered, a dose
Atazanavir Cmax: ↓23% (↓36% ↓8%)* increase of REYATAZ to
Atazanavir Cmin: ↓25% (↓47% ↑7%)* 400 mg with 100 mg of
In HIV-infected patients with atazanavir/ritonavir at an increased dose ritonavir is recommended. A
of 400/100 mg once daily dose equivalent to famotidine
Famotidine 20 mg twice daily Atazanavir AUC: ↑18% (↑6.5% ↑30%)* 40 mg twice daily should not
Atazanavir Cmax: ↑18% (↑6.7% ↑31%)* be exceeded.
Atazanavir Cmin: ↑24% (↑10% ↑39%)*
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) quetiapine (HOS-086150) protease (HOS-085623) famotidine (HOS-112087) tenofovir disoproxil (HOS-108843) lead (HOS-085592) fumarate (HOS-108845) tenofovir disoproxil fumarate (HOS-110471) ritonavir (HOS-084521) lurasidone (HOS-086148)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage d69eeb45d796d1cd8f98e48958156005dc8ba777a37e1a215ebb755a767192dc · Zeichen 30340–35663 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 51–52
HOS-112182 · Präparat HOS-093615
51
Medicinal products by Interaction Recommendations
therapeutic area concerning co-administration
Famotidine 40 mg twice daily Atazanavir AUC: ↔2.3% (↓13% ↑10%)*
Atazanavir Cmax: ↔5% (↓17% ↑8.4%)*
Atazanavir Cmin: ↔1.3% (↓10% ↑15)*
*When compared to atazanavir 300 mg
once daily with ritonavir 100 mg once daily
and tenofovir disoproxil fumarate 300 mg
all as a single dose with food. When
compared to atazanavir 300 mg with
ritonavir 100 mg without tenofovir
disoproxil fumarate,, atazanavir
concentrations are expected to be
additionally decreased by about 20%.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) famotidine (HOS-112087) fumarate (HOS-108845) tenofovir disoproxil fumarate (HOS-110471) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 2052af8108a80318b3cccb01a97ff4ba8440a5a6e22ac83aa15556f86a729697 · Zeichen 35722–36749 im Abschnitt
Wechselwirkungen · Isentress
ISENTRESS 400 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-119074 · Präparat HOS-094905
etravirine AUC 10 %
etravirine C12hr 17 %
etravirine Cmax 4 %
Nucleoside/tide reverse transcriptase inhibitors
tenofovir disoproxil fumarate raltegravir AUC 49 % No dose adjustment required
(raltegravir 400 mg Twice Daily) raltegravir C12hr 3 % for raltegravir or tenofovir
raltegravir Cmax ↑ 64 % disoproxil fumarate.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) etravirine (HOS-088088) fumarate (HOS-108845) tenofovir disoproxil fumarate (HOS-110471)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage 881d4462d52eb8570be13969614f19fb5d4db420bd37a3f3b99cefccf74096f0 · Zeichen 6515–7003 im Abschnitt
Wechselwirkungen · Isentress
ISENTRESS 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 29
HOS-119134 · Präparat HOS-094905
In drug interaction studies performed using raltegravir 400 mg twice daily, raltegravir did not have a
clinically meaningful effect on the pharmacokinetics of etravirine, maraviroc, tenofovir disoproxil
fumarate, hormonal contraceptives, methadone, midazolam or boceprevir. These findings can be
extended to raltegravir 1,200 mg once daily and no dosage adjustment is required for these agents.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) etravirine (HOS-088088) tenofovir disoproxil (HOS-108843) boceprevir (HOS-090617) maraviroc (HOS-086186) fumarate (HOS-108845) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage e3dde6ea7dd2eac6b5635674365bf53e12d9474eaf7c2520f07a29318f738e82 · Zeichen 1294–1688 im Abschnitt
Wechselwirkungen · Isentress
ISENTRESS 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 29
HOS-119143 · Präparat HOS-094905
Previous studies of raltegravir 400 mg twice daily showed that co-administration of tenofovir
disoproxil fumarate (a component of emtricitabine/tenofovir disoproxil fumarate) increased raltegravir
exposure. Emtricitabine/tenofovir disoproxil fumarate was identified to increase raltegravir 1,200 mg
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) fumarate (HOS-108845) tenofovir disoproxil fumarate (HOS-110471) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage 275469c6723c1e5d5c26b8aedca59d88eab8786e70b5203f4e04984353ef1a83 · Zeichen 4824–5122 im Abschnitt
Wechselwirkungen · Isentress
ISENTRESS 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 31
HOS-119156 · Präparat HOS-094905
tenofovir AUC 10%
tenofovir C24hr 13% No dose adjustment required
tenofovir Cmax ↓ 23% for raltegravir (400 mg twice
emtricitabine and tenofovir Population PK analysis showed daily and 1,200 mg once daily)
or tenofovir disoproxil
disoproxil fumarate that the effect of
emtricitabine/tenofovir fumarate.
(raltegravir 1,200 mg (2 x 600 mg)
Once Daily) disoproxil fumarate on
raltegravir pharmacokinetics
was minimal (12% increase in
relative bioavailability), and
was not statistically or clinically
significant.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) tenofovir disoproxil (HOS-108843) fumarate (HOS-108845) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage c64b39052f9c3c1693753c333ecbde674ac0c74bcde262337470853c0e47b9f7 · Zeichen 9606–10659 im Abschnitt
Wechselwirkungen · Isentress
ISENTRESS 25 mg chewable tablets ISENTRESS 100 mg chewable tablets · Abschnitt 4.5 · PDF-Seite 56
HOS-119231 · Präparat HOS-094905
etravirine AUC 10 %
etravirine C12hr 17 %
etravirine Cmax 4 %
Nucleoside/tide reverse transcriptase inhibitors
tenofovir disoproxil fumarate raltegravir AUC 49 % No dose adjustment required
(raltegravir 400 mg Twice Daily) raltegravir C12hr 3 % for raltegravir or tenofovir
raltegravir Cmax ↑ 64 % disoproxil fumarate.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) etravirine (HOS-088088) fumarate (HOS-108845) tenofovir disoproxil fumarate (HOS-110471)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage 881d4462d52eb8570be13969614f19fb5d4db420bd37a3f3b99cefccf74096f0 · Zeichen 6526–7014 im Abschnitt
Wechselwirkungen · Isentress
ISENTRESS 100 mg granules for oral suspension · Abschnitt 4.5 · PDF-Seite 80
HOS-119302 · Präparat HOS-094905
etravirine AUC 10 %
etravirine C12hr 17 %
etravirine Cmax 4 %
Nucleoside/tide reverse transcriptase inhibitors
tenofovir disoproxil fumarate raltegravir AUC 49 % No dose adjustment required
(raltegravir 400 mg Twice Daily) raltegravir C12hr 3 % for raltegravir or tenofovir
raltegravir Cmax ↑ 64 % disoproxil fumarate.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) etravirine (HOS-088088) fumarate (HOS-108845) tenofovir disoproxil fumarate (HOS-110471)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage 881d4462d52eb8570be13969614f19fb5d4db420bd37a3f3b99cefccf74096f0 · Zeichen 6231–6719 im Abschnitt
Wechselwirkungen · Tecfidera
Tecfidera 120 mg gastro-resistant hard capsules Tecfidera 240 mg gastro-resistant hard capsules · Abschnitt 4.5 · PDF-Seite 7
HOS-127574 · Präparat HOS-096433
In humans, dimethyl fumarate is extensively metabolised by esterases before it reaches the systemic
circulation and further metabolism occurs through the tricarboxylic acid cycle, with no involvement of
the cytochrome P450 (CYP) system. Potential interaction risks were not identified from in vitro CYP-
inhibition and induction studies, a p-glycoprotein study, or studies of the protein binding of dimethyl
fumarate and monomethyl fumarate (the primary metabolite of dimethyl fumarate).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fumarate (HOS-108845) monomethyl fumarate (HOS-127576)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-06T16:30:00Z · SHA-256 c529e0432acf9767ce48e42408ea2f72e957004be1c6f8e00714d8bd22b2a5fe · Passage 1ec4bb3a34ec21574c5b2e3709b96553d947e84f1c05abc8384e0c0a64ffb46d · Zeichen 2001–2488 im Abschnitt
Wechselwirkungen · Harvoni
Harvoni 90 mg/400 mg film-coated tablets Harvoni 45 mg/200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-132224 · Präparat HOS-097208
Expected:
↔ Sofosbuvir
↔ GS-331007
HIV ANTIVIRAL AGENTS: REVERSE TRANSCRIPTASE INHIBITORS
Efavirenz/ emtricitabine/ Efavirenz No dose adjustment of Harvoni or efavirenz/
tenofovir disoproxil ↔ Cmax 0.87 (0.79, 0.97) emtricitabine/ tenofovir disoproxil fumarate is
fumarate ↔ AUC 0.90 (0.84, 0.96) required.
(600 mg/ 200 mg/ 300 mg/ ↔ Cmin 0.91 (0.83, 0.99)
once daily)/ ledipasvir
(90 mg once daily)c/ Emtricitabine
sofosbuvir (400 mg once ↔ Cmax 1.08 (0.97, 1.21)
daily)c, d ↔ AUC 1.05 (0.98, 1.11)
↔ Cmin 1.04 (0.98, 1.11)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir disoproxil (HOS-108843) fumarate (HOS-108845) efavirenz (HOS-087947) tenofovir disoproxil fumarate (HOS-110471) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-10T14:39:00Z · SHA-256 5d503d87078c6a22bb188ba98b9837581fe648589d1f57d0325892e2bbaabbb1 · Passage 930e244e06b3d55169ce9fcb691836bb5c16c1b91a8bd1572967d18fea8d17dd · Zeichen 14180–14843 im Abschnitt
Wechselwirkungen · Harvoni
Harvoni 90 mg/400 mg film-coated tablets Harvoni 45 mg/200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12–13
HOS-132231 · Präparat HOS-097208
12
Medicinal product by Effects on medicinal Recommendation concerning co-administration
therapeutic areas product levels. with Harvoni
Mean ratio (90%
confidence interval) for
AUC, Cmax, Cmina, b
Emtricitabine/ rilpivirine/ Emtricitabine No dose adjustment of Harvoni or emtricitabine/
tenofovir disoproxil ↔ Cmax 1.02 (0.98, 1.06) rilpivirine/ tenofovir disoproxil fumarate is
fumarate ↔ AUC 1.05 (1.02, 1.08) required.
(200 mg/ 25 mg/ 300 mg ↔ Cmin 1.06 (0.97, 1.15)
once daily)/ ledipasvir
(90 mg once daily)c/ Rilpivirine
sofosbuvir (400 mg once ↔ Cmax 0.97 (0.88, 1.07)
daily)c, d ↔ AUC 1.02 (0.94, 1.11)
↔ Cmin 1.12 (1.03, 1.21)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir disoproxil (HOS-108843) fumarate (HOS-108845) rilpivirine (HOS-088090) tenofovir disoproxil fumarate (HOS-110471) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-10T14:39:00Z · SHA-256 5d503d87078c6a22bb188ba98b9837581fe648589d1f57d0325892e2bbaabbb1 · Passage a559760adca24d69fc073a66d500f39ce065ec749550bb818e89052fe84dcf57 · Zeichen 15636–16548 im Abschnitt
Wechselwirkungen · Harvoni
Harvoni 90 mg/400 mg film-coated tablets Harvoni 45 mg/200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14
HOS-132241 · Präparat HOS-097208
GS-331007
↔ Cmax 1.13 (1.08, 1.19)
↔ AUC 1.23 (1.18, 1.29)
↔ Cmin 1.28 (1.21, 1.36)
Atazanavir boosted with Atazanavir When given with tenofovir disoproxil fumarate used
ritonavir (300 mg/ 100 mg ↔ Cmax 1.07 (0.99, 1.14) in conjunction with atazanavir/ritonavir, Harvoni
once daily) + emtricitabine/ ↔ AUC 1.27 (1.18, 1.37) increased the concentration of tenofovir.
tenofovir disoproxil ↑ Cmin 1.63 (1.45, 1.84)
fumarate (200 mg/ 300 mg The safety of tenofovir disoproxil fumarate in the
once daily)/ ledipasvir Ritonavir setting of Harvoni and a pharmacokinetic enhancer
(90 mg once daily)c/ ↔ Cmax 0.86 (0.79, 0.93) (e.g. ritonavir or cobicistat) has not been
sofosbuvir (400 mg once ↔ AUC 0.97 (0.89, 1.05) established.
daily)c, d ↑ Cmin 1.45 (1.27, 1.64)
The combination should be used with caution with
Dosed simultaneouslyf Emtricitabine frequent renal monitoring, if other alternatives are
↔ Cmax 0.98 (0.94, 1.02) not available (see section 4.4).
↔ AUC 1.00 (0.97, 1.04)
↔ Cmin 1.04 (0.96, 1.12) Atazanavir concentrations are also increased, with a
risk for an increase in bilirubin levels/icterus. That
Tenofovir risk is even higher if ribavirin is used as part of the
↑ Cmax 1.47 (1.37, 1.58) HCV treatment.
↔ AUC 1.35 (1.29, 1.42)
↑ Cmin 1.47 (1.38, 1.57)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) atazanavir (HOS-086180) cobicistat (HOS-088111) tenofovir disoproxil (HOS-108843) ribavirin (HOS-088127) fumarate (HOS-108845) tenofovir disoproxil fumarate (HOS-110471) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-10T14:39:00Z · SHA-256 5d503d87078c6a22bb188ba98b9837581fe648589d1f57d0325892e2bbaabbb1 · Passage b3a267dfa6c6fe2a6060e8366ff7ee2223f8568c795a4d6dabbbcb66bac5a2b3 · Zeichen 19580–21475 im Abschnitt
Wechselwirkungen · Harvoni
Harvoni 90 mg/400 mg film-coated tablets Harvoni 45 mg/200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 15
HOS-132247 · Präparat HOS-097208
GS-331007
↔ Cmax 0.97 (0.90, 1.05)
↔ AUC 1.24 (1.18, 1.30)
Darunavir boosted with Darunavir When given with darunavir/ritonavir used in
ritonavir (800 mg/ 100 mg ↔ Cmax 1.01 (0.96, 1.06) conjunction with tenofovir disoproxil fumarate,
once daily) + emtricitabine/ ↔ AUC 1.04 (0.99, 1.08) Harvoni increased the concentration of tenofovir.
tenofovir disoproxil ↔ Cmin 1.08 (0.98, 1.20)
fumarate (200 mg/ 300 mg The safety of tenofovir disoproxil fumarate in the
once daily)/ ledipasvir Ritonavir setting of Harvoni and a pharmacokinetic enhancer
(90 mg once daily)c/ ↔ Cmax 1.17 (1.01, 1.35) (e.g. ritonavir or cobicistat) has not been
sofosbuvir (400 mg once ↔ AUC 1.25 (1.15, 1.36) established.
daily)c, d ↑ Cmin 1.48 (1.34, 1.63)
The combination should be used with caution with
Dosed simultaneouslyf Emtricitabine frequent renal monitoring, if other alternatives are
↔ Cmax 1.02 (0.96, 1.08) not available (see section 4.4).
↔ AUC 1.04 (1.00, 1.08)
↔ Cmin 1.03 (0.97, 1.10)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) cobicistat (HOS-088111) tenofovir disoproxil (HOS-108843) fumarate (HOS-108845) darunavir (HOS-086181) tenofovir disoproxil fumarate (HOS-110471) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-10T14:39:00Z · SHA-256 5d503d87078c6a22bb188ba98b9837581fe648589d1f57d0325892e2bbaabbb1 · Passage de81a39daa19e59fe5d31271fac488e87aa1e28fbf50a2af0cff704b2ad62c51 · Zeichen 23531–24899 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.